Review
Oncology
Anneloes van Duijn, Sjoerd H. Van der Burg, Ferenc A. Scheeren
Summary: This article focuses on the interactions between myeloid immune cells and anti-tumor immune responses in the tumor microenvironment. Blocking the CD47/SIRP alpha axis can enhance adaptive immune response. The potential therapeutic role of CD47/SIRP alpha axis is discussed in tumors with acquired resistance to classic immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Rama Krishna Narla, Hardik Modi, Daniel Bauer, Mahan Abbasian, Jim Leisten, Joseph R. Piccotti, Stephan Kopytek, Brendan P. Eckelman, Quinn Deveraux, John Timmer, Dan Zhu, Lilly Wong, Laure Escoubet, Heather K. Raymon, Kandasamy Hariharan
Summary: CD47, overexpressed on tumor cells, inhibits phagocytosis by macrophages, while CC-90002, a humanized anti-CD47 antibody, enhances phagocytosis of tumor cells and inhibits tumor growth by recruiting macrophages to bind with tumor cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Nan Qin, Lena Bluemel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Allison Cole, Joselyn Cruz-Cruz, Claus M. Graef, Matthias Woelfl, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stuehler, Stephen T. Keir, Darell D. Bigner, Julia Hauer, Thomas Beez, Christiane B. Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K. Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H. Cheshier, Guido Reifenberger, Arndt Borkhardt, Thomas Kurz, Marc Remke, Siddhartha Mitra
Summary: In this study, the researchers discovered that the inhibitor CI-994, which targets epigenetic modifiers, has significant therapeutic effects on MYC-driven medulloblastoma. By modulating the CD47-SIRP alpha phagocytosis checkpoint pathway and enhancing macrophage phagocytosis, CI-994 provides a new strategy to enhance cancer immunotherapy responses.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Developmental Biology
Jing Li, Shumin Yan, Qiuju Li, Yufei Huang, Miaomiao Ji, Xue Jiao, Ming Yuan, Guoyun Wang
Summary: Peritoneal macrophages play a significant role in the progression of endometriosis. Targeting CD47 can improve the phagocytosis of macrophages and induce apoptosis of ectopic endometrial stromal cells, suggesting that immunotherapy based on the CD47-SIRP alpha signaling pathway has potential in treating endometriosis.
MOLECULAR HUMAN REPRODUCTION
(2022)
Article
Medicine, Research & Experimental
Satoka Shiratori-Aso, Daigo Nakazawa, Takashi Kudo, Masatoshi Kanda, Yusho Ueda, Kanako Watanabe-Kusunoki, Saori Nishio, Sari Iwasaki, Takahiro Tsuji, Sakiko Masuda, Utano Tomaru, Akihiro Ishizu, Tatsuya Atsumi
Summary: Neutrophil extracellular trap (NET) formation is an important part of immune defense and cell death. Excessive NET formation can be found in patients with anti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitis (AAV), leading to disease progression. The CD47 signaling pathway plays a role in the escape of pathogenic NETs from efferocytosis, resulting in the development of necrotizing vasculitis. Inhibition of CD47 can protect against glomerulonephritis in AAV by restoring efferocytosis of ANCA-induced NETs.
Review
Immunology
Yan Yang, Zheng Yang, Yun Yang
Summary: The flourishing of immunological therapy for cancer has sparked great enthusiasm for exploring novel targets. CD47-targeted bispecific antibodies are currently under clinical research, following the approval of blinatumomab for acute lymphoblastic leukemia. The review discussed the basics of bispecific antibodies, ongoing phase I studies, toxicity issues, and potential resistance mechanisms to CD47-targeted therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Yantao Duan, Shun Li, Binhao Huang, Yi Dou, Pengfei Kong, Wei Kang, Dazhi Xu
Summary: The study aimed to enhance antitumour immunity in Epstein-Barr virus-associated gastric cancer (EBVaGC). RNA-seq analysis was performed to compare the differential expression genes between EBVaGC and EBV-negative gastric cancer (EBVnGC) patients. Immunohistochemistry was used to analyze the expression levels of CD68, CD163, and CD47. Different subsets of macrophages were investigated using a coincubation model. The study found that CD68, CD163, and CD47 were significantly upregulated in EBVaGC, and their expression levels were associated with poor prognoses. Macrophages coincubated with EBV+ AGS cells tended to be immunosuppressed, which could be reversed by CD47 deficiency or blocking CD47. EBV activated the cGAS-STING pathway, which stimulated CD47 expression and inhibited macrophage phagocytosis. Anti-CD47 therapy activated the cGAS-STING signaling, resulting in the production of IFN-beta and the activation of antitumour immunity. These findings provide a promising new strategy for CD47-targeted immunotherapy in EBVaGC.
CLINICAL IMMUNOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Xin-Yu Ben, Ya-Ru Wang, Hui-Hui Zheng, De-Xian Li, Rui Ren, Pan-Li Ni, Hai-Ying Zhang, Ren-Jun Feng, Yun-Qing Li, Qi-Fu Li, Xi-Nan Yi
Summary: The study aimed to establish a theoretical and practical foundation for the use of exosomes (EXOs) with high levels of CD47 as stable and efficient drug carriers. Results showed that EXOsCD47 exhibited improved immune escape and resistance to phagocytosis compared to control EXOs. These findings suggest that engineered EXOsCD47 could serve as potential drug carriers.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Jia-Qi Luo, Rong Liu, Fang-Man Chen, Jing-Yang Zhang, Sui-Juan Zheng, Dan Shao, Jin-Zhi Du
Summary: A degradable mesoporous silica nanoparticle (MSN) has been developed for simultaneous delivery of anti-CD47 antibodies (aCD47) and doxorubicin (DOX) in cancer chemo-immunotherapy. The nanocarrier, aCD47-DMSN, blocks the CD47-SIRP alpha axis and induces immunogenic tumor cell death for enhanced phagocytosis by macrophages. This study provides a promising nanoplatform for modulating macrophage phagocytosis in cancer therapy.
Article
Oncology
Zhilei Cui, Dengfei Xu, Fafu Zhang, Jinyuan Sun, Lin Song, Wenjing Ye, Junxiang Zeng, Min Zhou, Zhengshang Ruan, Linlin Zhang, Rongrong Ren
Summary: The study found that cisplatin (CDDP) increased the expression of CD47 in lung cancer cells, while blocking CD47 enhanced the phagocytic activity of macrophages on CDDP-treated tumor cells. The combination treatment of CDDP and aCD47 exhibited anti-tumor effects and modulated immune cell populations and cytokine levels in the tumor-bearing model.
EXPERIMENTAL CELL RESEARCH
(2021)
Article
Oncology
Xu Cao, Bolei Li, Jing Chen, Jessica Dang, Siqi Chen, E. Gulsen Gunes, Bo Xu, Lei Tian, Sabina Muend, Mustafa Raoof, Christiane Querfeld, Jianhua Yu, Steven T. Rosen, Yingyu Wang, Mingye Feng
Summary: The study found that blocking CD47 and using cabazitaxel can significantly promote the programmed cell removal of TNBC cells, inhibiting tumor development and metastasis, providing a promising new strategy for TNBC treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Ying Ying Yiu, Paige S. Hansen, Laughing Bear Torrez Dulgeroff, Grace Blacker, Lara Myers, Sarah Galloway, Eric Gars, Olivia Colace, Paul Mansfield, Kim J. Hasenkrug, Irving L. Weissman, Michal Caspi Tal
Summary: CD47 blockade is a promising immuno-oncology treatment that promotes clearance of cancer cells, but it also leads to depletion of splenic marginal zone B cells, which is dependent on intact CD47-SIRP alpha interactions.
JOURNAL OF IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xinlei Tian, Min Guo, Xiaoya Zhang, Lingfeng Guo, Nan Lan, Yaojun Cheng, Yannan Han, Mingxin Wang, Zhonglu Peng, Changlin Zhou, Hongye Fan
Summary: This study investigated whether Strongylocentrotus nudus eggs polysaccharide (SEP), a non-toxic extract from seafood, contributes to host defense against bacterial infection. The results showed that SEP enhanced bacterial clearance by promoting phagocytosis by macrophages and protected mice from bacterial infection.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Yu-Chi Chen, Wei Shi, Jia-Jie Shi, Jin-Jian Lu
Summary: The development of CD47 targeting agents faces hematotoxicity as a common side effect, but strategies such as changing the mode of administration and using bispecific antibodies can mitigate this issue.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Chaoyu Wang, Chengtao Sun, Mengzhen Li, Bing Xia, Yi Wang, Li Zhang, Yanyan Zhang, Juan Wang, Feifei Sun, Suying Lu, Jia Zhu, Junting Huang, Yizhuo Zhang
Summary: The study found that AML patients had significantly higher levels of CD47 expression on cells compared to healthy individuals. Using novel fully human anti-CD47 monoclonal antibodies increased macrophage-mediated phagocytosis of AML cells in vitro and prolonged the survival time of mice in vivo, enhancing the elimination of AML cells.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)